Which statement is NOT true regarding EFAD in CF?

Which statement is NOT true regarding EFAD in CF?

• A. Routine omega-3 supplementation is essential in CF management
• B. Biochemical EFAD may be seen in both pancreatic sufficient and insufficient patients
• C. Those with moderate to severe lung disease are at high risk for EFAD
• D. Poor growth and pulmonary status correlate with biochemical markers of EFAD

Answer: (A)

In cystic fibrosis, essential fatty acid deficiency arises when fat absorption is impaired and dietary intake of fats isn’t enough to meet needs. EFAD is diagnosed biochemical via markers such as decreased essential fatty acids (like linoleic and arachidonic acids) and an elevated Mead acid ratio, reflecting an imbalance when essential fats are scarce. This deficiency can occur even in patients who are pancreatic sufficient, as malabsorption or increased needs can still occur, not strictly tied to pancreatic status. Those with moderate to severe lung disease are at higher risk because of greater metabolic demands and often more pronounced malabsorption, so poorer growth and worse pulmonary status frequently accompany EFAD and align with biochemical EFAD markers. In short, EFAD tends to track with overall disease burden and nutritional intake, not solely with whether the pancreas is producing enzymes. Routine omega-3 supplementation is not considered essential in CF management. While omega-3s may be used in some settings or explored for potential benefits, they are not a standard, universally required component of CF care. The mainstay remains optimizing fat absorption with pancreatic enzyme replacement and ensuring adequate intake of fat-soluble vitamins and calories, with targeted supplementation guided by biochemical EFAD findings when indicated.

In cystic fibrosis, essential fatty acid deficiency arises when fat absorption is impaired and dietary intake of fats isn’t enough to meet needs. EFAD is diagnosed biochemical via markers such as decreased essential fatty acids (like linoleic and arachidonic acids) and an elevated Mead acid ratio, reflecting an imbalance when essential fats are scarce.

This deficiency can occur even in patients who are pancreatic sufficient, as malabsorption or increased needs can still occur, not strictly tied to pancreatic status. Those with moderate to severe lung disease are at higher risk because of greater metabolic demands and often more pronounced malabsorption, so poorer growth and worse pulmonary status frequently accompany EFAD and align with biochemical EFAD markers. In short, EFAD tends to track with overall disease burden and nutritional intake, not solely with whether the pancreas is producing enzymes.

Routine omega-3 supplementation is not considered essential in CF management. While omega-3s may be used in some settings or explored for potential benefits, they are not a standard, universally required component of CF care. The mainstay remains optimizing fat absorption with pancreatic enzyme replacement and ensuring adequate intake of fat-soluble vitamins and calories, with targeted supplementation guided by biochemical EFAD findings when indicated.